

Whole-genome landscapes of major melanoma subtype

Nature

545, 175-180

DOI: [10.1038/nature22071](https://doi.org/10.1038/nature22071)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of melanoma revealed. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 393-393.	12.5	2
2	Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6946-6957.	3.2	73
3	Mutations of RNA splicing factors in hematological malignancies. <i>Cancer Letters</i> , 2017, 409, 1-8.	3.2	14
4	<i>KIT</i> mutations and <i>CD117</i> overexpression are markers of better progression-free survival in vulvar melanomas. <i>British Journal of Dermatology</i> , 2017, 177, 1376-1384.	1.4	16
5	Mutations in the promoter of the telomerase gene <i>TERT</i> contribute to tumorigenesis by a two-step mechanism. <i>Science</i> , 2017, 357, 1416-1420.	6.0	224
6	Fluorescence in situ hybridisation as an ancillary tool in the diagnosis of acral melanoma: a review of 44 cases. <i>Pathology</i> , 2017, 49, 740-749.	0.3	22
7	Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1. <i>Nature Communications</i> , 2017, 8, 2249.	5.8	22
9	Combating NRAS mutant melanoma: from bench to bedside. <i>Melanoma Management</i> , 2017, 4, 183-186.	0.1	8
10	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2017, 5, 28.	1.3	22
11	The MeLiM Minipig: An Original Spontaneous Model to Explore Cutaneous Melanoma Genetic Basis. <i>Frontiers in Genetics</i> , 2017, 8, 146.	1.1	18
12	Precision Oncology: The Promise of Big Data and the Legacy of Small Data. <i>Frontiers in ICT</i> , 2017, 4, .	3.6	4
13	Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. <i>Melanoma Management</i> , 2017, 4, 147-149.	0.1	1
14	Loss of the chromatin modifier Kdm2aa causes Brafv600E-independent spontaneous melanoma in zebrafish. <i>PLoS Genetics</i> , 2017, 13, e1006959.	1.5	13
15	Vascular abnormalities and development of hypoxia in microscopic melanoma xenografts. <i>Journal of Translational Medicine</i> , 2017, 15, 241.	1.8	25
16	Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 469-476.	1.4	19
17	Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor-2 protein expression in 1479 cases of lung adenocarcinoma in China. <i>Thoracic Cancer</i> , 2018, 9, 439-444.	0.8	2
18	Polyunsaturated fatty acids and risk of melanoma: A Mendelian randomisation analysis. <i>International Journal of Cancer</i> , 2018, 143, 508-514.	2.3	18
19	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. <i>Nature</i> , 2018, 555, 371-376.	13.7	649

#	ARTICLE	IF	CITATIONS
20	Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. <i>Nature Reviews Cancer</i> , 2018, 18, 341-358.	12.8	248
21	Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. <i>Oncogene</i> , 2018, 37, 4058-4072.	2.6	42
22	Pilot study on the correlation between dermoscopic patterns and fluorescence <i>in situ</i> hybridization findings using whole-slide digital imaging for acral volar melanocytic lesions. <i>Journal of Dermatology</i> , 2018, 45, 830-836.	0.6	5
23	Melanoma: What do all the mutations mean?. <i>Cancer</i> , 2018, 124, 3490-3499.	2.0	131
24	The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma. <i>Targeted Oncology</i> , 2018, 13, 437-446.	1.7	27
25	Co-targeting <i>BET</i> and <i>MEK</i> as salvage therapy for <i>MAPK</i> and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	79
26	Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma. <i>Human Pathology</i> , 2018, 75, 137-145.	1.1	10
27	Clinical, Epidemiological, and Molecular Heterogeneity in Acral Melanoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 254-255.	0.3	10
28	Prognostic features for acral lentiginous melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 311-312.	1.4	7
29	Ultraviolet light and melanoma. <i>Journal of Pathology</i> , 2018, 244, 578-585.	2.1	47
30	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3
31	Diff-seq: A high throughput sequencing-based mismatch detection assay for DNA variant enrichment and discovery. <i>Nucleic Acids Research</i> , 2018, 46, e42-e42.	6.5	7
32	Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. <i>Annals of Surgical Oncology</i> , 2018, 25, 885-893.	0.7	7
33	Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features. <i>Journal of Investigative Dermatology</i> , 2018, 138, 933-945.	0.3	67
34	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	13.7	269
35	Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy. <i>Journal of Proteomics</i> , 2018, 188, 119-138.	1.2	4
36	Telomere sequence content can be used to determine ALT activity in tumours. <i>Nucleic Acids Research</i> , 2018, 46, 4903-4918.	6.5	40
37	Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment. <i>Human Genomics</i> , 2018, 12, 20.	1.4	11

#	ARTICLE	IF	CITATIONS
38	Genetics of metastasis: melanoma and other cancers. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 379-391.	1.7	73
39	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , 2018, 19, 672-681.	5.1	732
40	Whole-Exome Sequencing of Acquired Nevi Identifies Mechanisms for Development and Maintenance of Benign Neoplasms. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1636-1644.	0.3	43
41	Functional interplay between secreted ligands and receptors in melanoma. <i>Seminars in Cell and Developmental Biology</i> , 2018, 78, 73-84.	2.3	16
42	Epigenetics of malignant melanoma. <i>Seminars in Cancer Biology</i> , 2018, 51, 80-88.	4.3	95
43	Chromatin modification: A novel insight into BRAF-independent spontaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 9-10.	1.5	0
44	Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 607-621.	2.4	53
45	Ubiquitylation at the crossroads of development and disease. <i>Nature Reviews Molecular Cell Biology</i> , 2018, 19, 59-70.	16.1	430
46	Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure. <i>Journal of Investigative Dermatology</i> , 2018, 138, 384-393.	0.3	44
47	A 14-protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700094.	0.8	0
48	Medical bioinformatics in melanoma. <i>Current Opinion in Oncology</i> , 2018, 30, 113-117.	1.1	13
49	Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. <i>European Journal of Cancer</i> , 2018, 89, 90-101.	1.3	19
50	Analysis of TSC1 mutation spectrum in mucosal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 257-267.	1.2	12
51	Immuno-oncology from the perspective of somatic evolution. <i>Seminars in Cancer Biology</i> , 2018, 52, 75-85.	4.3	15
52	BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. <i>Brain Pathology</i> , 2018, 28, 663-673.	2.1	51
53	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , 2018, 31, 24-38.	2.9	324
54	Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma. <i>British Journal of Cancer</i> , 2018, 118, 98-105.	2.9	52
55	Insights from structures of cancer-relevant pre-mRNA splicing factors. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 57-66.	1.5	16

#	ARTICLE	IF	CITATIONS
56	Trajectories of premalignancy during the journey from melanocyte to melanoma. <i>Pathology</i> , 2018, 50, 16-23.	0.3	23
57	Genital mucosal melanoma with somatic SF3B1 R625C mutation. <i>European Journal of Dermatology</i> , 2018, 28, 414-415.	0.3	2
58	Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience. <i>Melanoma Research</i> , 2018, 28, 586-591.	0.6	11
59	Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. <i>European Journal of Cancer</i> , 2018, 105, 114-126.	1.3	52
60	Identification of Primary and Metastatic Melanoma based on Copy Number Variation. , 2018, 2018, 1319-1322.		1
61	Combatting mucosal melanoma: recent advances and future perspectives. <i>Melanoma Management</i> , 2018, 5, MMT11.	0.1	75
62	A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the OncoPrint Tumor Mutation Load Assay. <i>Translational Lung Cancer Research</i> , 2018, 7, 616-630.	1.3	41
63	Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers. <i>PLoS Genetics</i> , 2018, 14, e1007849.	1.5	60
64	Nucleosome positions establish an extended mutation signature in melanoma. <i>PLoS Genetics</i> , 2018, 14, e1007823.	1.5	33
65	Melanoma Cell Death Mechanisms. <i>Chonnam Medical Journal</i> , 2018, 54, 135.	0.5	29
66	Mitochondrial transcription factor A (TFAM) shapes metabolic and invasion gene signatures in melanoma. <i>Scientific Reports</i> , 2018, 8, 14190.	1.6	41
67	Frontiers in pigment cell and melanoma research. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 728-735.	1.5	10
69	The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. <i>Current Oncology Reports</i> , 2018, 20, 87.	1.8	119
70	Dimerization quality control via ubiquitylation. <i>Science</i> , 2018, 362, 151-152.	6.0	4
71	Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. <i>Pharmacogenomics</i> , 2018, 19, 1303-1310.	0.6	0
72	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. <i>Pathology</i> , 2018, 50, 703-710.	0.3	21
73	Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with <i>BRAF</i> Mutation. <i>Annals of Dermatology</i> , 2018, 30, 556.	0.3	4
74	Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. <i>BMC Cancer</i> , 2018, 18, 1054.	1.1	15

#	ARTICLE	IF	CITATIONS
75	Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort. <i>Scientific Reports</i> , 2018, 8, 15962.	1.6	4
76	Human tumor genomics and zebrafish modeling identify <i>SPRED1</i> loss as a driver of mucosal melanoma. <i>Science</i> , 2018, 362, 1055-1060.	6.0	123
77	Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches. <i>Current Oncology Reports</i> , 2018, 20, 86.	1.8	61
78	Sun Exposure and Melanoma, Certainties and Weaknesses of the Present Knowledge. <i>Frontiers in Medicine</i> , 2018, 5, 235.	1.2	29
79	Dimerization quality control ensures neuronal development and survival. <i>Science</i> , 2018, 362, .	6.0	56
80	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	2.9	114
81	Melanoma. <i>Lancet</i> , The, 2018, 392, 971-984.	6.3	1,016
82	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	1.5	56
83	Identifying neoantigens for use in immunotherapy. <i>Mammalian Genome</i> , 2018, 29, 714-730.	1.0	28
84	The role of lipid signaling in the progression of malignant melanoma. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 245-255.	2.7	8
85	High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis. <i>Cancer Science</i> , 2018, 109, 1787-1798.	1.7	19
86	Chemical Modulation of WNT Signaling in Cancer. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 153, 245-269.	0.9	20
87	<i>TERT</i> copy gain predicts the outcome of high-dose interferon α -2b therapy in acral melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4097-4104.	1.0	28
88	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. <i>Drug Discovery Today</i> , 2018, 23, 1848-1872.	3.2	12
89	Pathways in melanoma development. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 68-76.	0.1	4
90	Biomarkers for Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 270.	1.3	47
91	Pathology and Genetics of Melanoma. , 2018, , .		0
92	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018, 8, 178.	1.3	53

#	ARTICLE	IF	CITATIONS
93	Multisite dependency of an E3 ligase controls monoubiquitylation-dependent cell fate decisions. <i>ELife</i> , 2018, 7, .	2.8	26
94	Telomere Maintenance Mechanisms in Cancer. <i>Genes</i> , 2018, 9, 241.	1.0	91
95	ETS transcription factors induce a unique UV damage signature that drives recurrent mutagenesis in melanoma. <i>Nature Communications</i> , 2018, 9, 2626.	5.8	111
96	Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 394.	1.8	78
97	Patterns of genomic evolution in advanced melanoma. <i>Nature Communications</i> , 2018, 9, 2665.	5.8	62
98	Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 287.	1.1	30
99	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. <i>British Journal of Cancer</i> , 2018, 119, 713-723.	2.9	9
100	A genome-wide net to catch and understand cancer. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	2
101	RHO GTPases in cancer: known facts, open questions, and therapeutic challenges. <i>Biochemical Society Transactions</i> , 2018, 46, 741-760.	1.6	58
102	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. <i>Clinical Cancer Research</i> , 2018, 24, 4494-4504.	3.2	28
103	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6511-6523.	3.2	62
104	Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies. <i>Frontiers in Medicine</i> , 2019, 6, 174.	1.2	49
105	Desmoplastic Melanoma. , 2019, , 469-481.		0
106	Molecular Diagnostics in Melanocytic Neoplasia. , 2019, , 629-650.		0
107	Acral Melanoma. , 2019, , 411-438.		0
108	Atypical BRAF and NRAS Mutations in Mucosal Melanoma. <i>Cancers</i> , 2019, 11, 1133.	1.7	47
109	Neuroblastoma rat sarcoma mutated melanoma: Thatâ€™s what we got so far. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 744-752.	1.5	4
110	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2987-2999.	0.8	126

#	ARTICLE	IF	CITATIONS
111	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019, 19, 805.	1.1	9
112	Clinical and genetic analysis of melanomas arising in acral sites. <i>European Journal of Cancer</i> , 2019, 119, 66-76.	1.3	34
113	Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas. <i>Modern Pathology</i> , 2019, 32, 1727-1733.	2.9	36
114	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	5.8	205
115	Identification of a functional polymorphism within the 3' untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma. <i>European Journal of Cancer</i> , 2019, 118, 70-81.	1.3	13
116	Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 805-812.	0.6	80
117	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. , 2019, 7, 180.		137
118	Acral Lentiginous Melanoma. , 2019, , 1-28.		1
119	A case report of cutaneous melanocytoma with <i>CRTC1</i> – <i>TRIM11</i> fusion: Is CMCT distinct from clear cell sarcoma of soft tissue?. <i>Pathology International</i> , 2019, 69, 496-501.	0.6	13
120	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. <i>BMC Cancer</i> , 2019, 19, 665.	1.1	42
121	Organization of DNA damage, excision repair, and mutagenesis in chromatin: A genomic perspective. <i>DNA Repair</i> , 2019, 81, 102645.	1.3	29
122	So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020. <i>Cancers</i> , 2019, 11, 1032.	1.7	46
123	Molecular background of skin melanoma development and progression: therapeutic implications. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 129-138.	0.4	22
124	Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. <i>Cancers</i> , 2019, 11, 845.	1.7	58
125	Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison. <i>Genes</i> , 2019, 10, 501.	1.0	87
126	Overexpression of microRNA-21 inhibits the growth and metastasis of melanoma cells by targeting MKK3. <i>Molecular Medicine Reports</i> , 2019, 20, 1797-1807.	1.1	7
127	Genome-Wide Analysis of Long Non-Coding RNA Profiles in Canine Oral Melanomas. <i>Genes</i> , 2019, 10, 477.	1.0	18
128	Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	9

#	ARTICLE	IF	CITATIONS
129	Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy. <i>JAMA Ophthalmology</i> , 2019, 137, 1444.	1.4	29
130	Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. <i>European Journal of Cancer</i> , 2019, 123, 1-10.	1.3	25
131	Telomere Length Maintenance and Its Transcriptional Regulation in Lynch Syndrome and Sporadic Colorectal Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1172.	1.3	46
132	Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2019, 9, 995.	1.3	14
133	Genomic sites hypersensitive to ultraviolet radiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24196-24205.	3.3	66
134	Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 486-495.	1.0	4
135	Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. <i>Cancer Science</i> , 2019, 110, 3434-3441.	1.7	13
136	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , 2019, 17, 289.	1.8	24
137	Affinity Purification of NF1 Protein-Protein Interactors Identifies Keratins and Neurofibromin Itself as Binding Partners. <i>Genes</i> , 2019, 10, 650.	1.0	11
138	N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells. <i>Cell Communication and Signaling</i> , 2019, 17, 114.	2.7	7
140	The Role of MET in Melanoma and Melanocytic Lesions. <i>American Journal of Pathology</i> , 2019, 189, 2138-2148.	1.9	21
141	Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. <i>Cancers</i> , 2019, 11, 1342.	1.7	22
142	Cancer Genetics and Therapeutics. , 2019, , .		6
143	Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. <i>Cancers</i> , 2019, 11, 1329.	1.7	9
144	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
145	BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. <i>Journal of Clinical Medicine</i> , 2019, 8, 1577.	1.0	9
146	Micro RNA Transcriptome Profile in Canine Oral Melanoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4832.	1.8	17
147	Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. <i>Nature Communications</i> , 2019, 10, 353.	5.8	99

#	ARTICLE	IF	CITATIONS
148	Fast-growing melanoma: a distinct entity or a superficial spreading melanoma with a brief horizontal phase?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 13-14.	1.3	7
149	Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. <i>Cell</i> , 2019, 176, 1113-1127.e16.	13.5	74
150	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 584.	1.3	14
151	Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.	1.3	79
152	Thymine DNA glycosylase as a novel target for melanoma. <i>Oncogene</i> , 2019, 38, 3710-3728.	2.6	28
153	Targeted Genomic Profiling of Acral Melanoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1068-1077.	3.0	118
154	SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 168-177.	2.1	25
155	Somatic mutational signatures in polyposis and colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2019, 69, 62-72.	2.7	14
156	The molecular clock in the skin, its functionality, and how it is disrupted in cutaneous melanoma: a new pharmacological target?. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3801-3826.	2.4	28
157	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1171-1178.	2.0	48
158	Fibroblast Growth Factor Receptor Signaling in Skin Cancers. <i>Cells</i> , 2019, 8, 540.	1.8	49
159	Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. <i>Cancer Science</i> , 2019, 110, 1995-2003.	1.7	31
160	Neoadjuvant dabrafenib combined with trametinib for resectable, stage III B&C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	5.1	126
161	Acral lentiginous melanoma and mucosal melanoma expressed less programmed death 1 ligand than cutaneous melanoma: a retrospective study of 73 Japanese melanoma patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e424-e426.	1.3	9
162	Biochemical reconstitution of UV-induced mutational processes. <i>Nucleic Acids Research</i> , 2019, 47, 6769-6782.	6.5	10
163	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
164	LNK suppresses interferon signaling in melanoma. <i>Nature Communications</i> , 2019, 10, 2230.	5.8	21
165	In perspective: An update on telomere targeting in cancer. <i>Molecular Carcinogenesis</i> , 2019, 58, 1581-1588.	1.3	41

#	ARTICLE	IF	CITATIONS
166	Melanoma. <i>Cmaj</i> , 2019, 191, E535-E535.	0.9	1
167	Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 86.	1.2	18
168	Treatment of Occupational Skin Cancer. , 2019, , 1-10.		0
169	Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness. <i>Neoplasia</i> , 2019, 21, 627-640.	2.3	36
170	Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi. <i>Cancers</i> , 2019, 11, 546.	1.7	8
171	Molecular Genomic Profiling of Melanocytic Nevus. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1762-1768.	0.3	55
172	Silencing of microRNA-27a facilitates autophagy and apoptosis of melanoma cells through the activation of the SYK-dependent mTOR signaling pathway. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13262-13274.	1.2	13
173	Distant metastasis due to heavily pigmented epithelioid melanoma with underlying <i>BRAF</i> V600E, <i>NOTCH1</i> , <i>ERBB3</i> , and <i>PTEN</i> mutations. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 613-618.	0.7	3
174	Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 54.	1.8	33
175	Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion. <i>Cancer Letters</i> , 2019, 452, 178-190.	3.2	32
176	Genomic Heterogeneity and Branched Evolution of Early Stage Primary Acral Melanoma Shown by Multiregional Microdissection Sequencing. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1526-1534.	0.3	7
177	Molecular Diagnostics in Melanoma: An Update. , 2019, , 73-88.		0
178	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 328-344.	2.9	160
179	Sunbeds and carcinogenesis: the need for new regulations and restrictions in Europe from the Euromelanoma perspective. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 104-109.	1.3	9
180	Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 937.	1.8	8
181	Recurrent Noncoding Mutations in Skin Cancers: UV Damage Susceptibility or Repair Inhibition as Primary Driver?. <i>BioEssays</i> , 2019, 41, e1800152.	1.2	10
182	Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. <i>Nature Medicine</i> , 2019, 25, 597-602.	15.2	61
183	Three cases of nivolumab therapy failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy. <i>Journal of Dermatology</i> , 2019, 46, 449-452.	0.6	3

#	ARTICLE	IF	CITATIONS
184	Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking. <i>Journal of Dental Research</i> , 2019, 98, 652-658.	2.5	14
185	Genomic Characterization of Differentiated Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2019, 34, 1.	1.3	37
186	Role of miRNAs in Melanoma Metastasis. <i>Cancers</i> , 2019, 11, 326.	1.7	64
187	MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways. <i>Theranostics</i> , 2019, 9, 945-960.	4.6	49
188	Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1769-1778.e2.	0.3	9
189	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. <i>Scientific Reports</i> , 2019, 9, 5154.	1.6	12
190	Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations. <i>Brain Tumor Pathology</i> , 2019, 36, 103-111.	1.1	5
191	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). <i>Translational Oncology</i> , 2019, 12, 828-835.	1.7	90
192	Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of <i>BRAF</i> -X1 mRNA. <i>RNA Biology</i> , 2019, 16, 865-878.	1.5	10
193	Targeting the ERK Signaling Pathway in Melanoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1483.	1.8	116
194	Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples. <i>BMC Medical Genomics</i> , 2019, 12, 31.	0.7	19
195	The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 685-693.	0.6	12
196	Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanoma. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 308-316.	0.8	12
197	Upregulated LncRNA <i>CCAT1</i> promotes hepatocellular carcinoma progression by functioning as miR-30c-2 sponge. <i>Cell Biochemistry and Function</i> , 2019, 37, 84-92.	1.4	26
198	Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations. <i>Clinical Cancer Research</i> , 2019, 25, 3548-3560.	3.2	74
199	Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors. <i>Modern Pathology</i> , 2019, 32, 957-966.	2.9	19
200	ASO Author Reflections: Subungual Melanomas of the Hand Present Diagnostic and Therapeutic Challenges. <i>Annals of Surgical Oncology</i> , 2019, 26, 1044-1045.	0.7	2
201	Intragenomic variability and extended sequence patterns in the mutational signature of ultraviolet light. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20411-20417.	3.3	22

#	ARTICLE	IF	CITATIONS
202	Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. <i>Melanoma Research</i> , 2019, 29, 483-490.	0.6	13
203	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	15.2	541
204	Mutational Profile of Driver Genes in Brazilian Melanomas. <i>Journal of Global Oncology</i> , 2019, 5, 1-14.	0.5	6
205	A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. <i>Scientific Reports</i> , 2019, 9, 17050.	1.6	42
206	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1905.	1.7	14
207	Integration of protein interaction and gene co-expression information for identification of melanoma candidate genes. <i>Melanoma Research</i> , 2019, 29, 126-133.	0.6	4
208	GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma. <i>Melanoma Research</i> , 2019, 29, 612-620.	0.6	14
210	Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 350.	1.8	44
211	Array Comparative Genomic Hybridization Analysis Reveals Significantly Enriched Pathways in Canine Oral Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1397.	1.3	13
212	A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 2041.	1.7	17
214	Clinical Application of Next-Generation Sequencing-Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 937-944.	1.9	14
216	Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. <i>American Journal of Dermatopathology</i> , 2019, 41, 264-272.	0.3	29
217	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. <i>International Journal of Cancer</i> , 2019, 144, 1049-1060.	2.3	54
218	Immune Checkpoints. , 2019, , 19-43.		0
219	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	1.3	31
220	The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in <i>BRAF/NRAS</i> wild-type melanomas. <i>Cancer</i> , 2019, 125, 586-600.	2.0	16
221	Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. <i>Molecular Carcinogenesis</i> , 2019, 58, 588-602.	1.3	37
222	Acral and Subungual Melanoma. , 2019, , 168-180.		0

#	ARTICLE	IF	CITATIONS
223	Mucosal Melanocytic Tumors. , 2019, , 274-284.		0
224	p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. <i>Cancer Cell</i> , 2019, 35, 46-63.e10.	7.7	50
225	Subungual Melanoma of the Hand. <i>Annals of Surgical Oncology</i> , 2019, 26, 1035-1043.	0.7	28
226	<i>BRAF</i> V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens. <i>Acta Cytologica</i> , 2019, 63, 10-16.	0.7	5
227	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. <i>International Journal of Cancer</i> , 2019, 144, 2303-2312.	2.3	95
228	Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients. <i>British Journal of Dermatology</i> , 2019, 180, 1230-1231.	1.4	29
229	The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 303-314.	1.5	17
230	Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian-Dutch Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 395-405.	0.7	16
231	Histogenesis of cutaneous malignant melanoma: The vast majority do not develop from melanocytic nevus but arise de novo as melanoma <i>in situ</i>. <i>Journal of Dermatology</i> , 2019, 46, 80-94.	0.6	11
232	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 7.	6.9	113
233	DNA polymerase δ contributes to genome-wide lagging strand synthesis. <i>Nucleic Acids Research</i> , 2019, 47, 2425-2435.	6.5	17
234	Translation regulation in skin cancer from a tRNA point of view. <i>Epigenomics</i> , 2019, 11, 215-245.	1.0	25
235	Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. <i>Modern Pathology</i> , 2019, 32, 330-337.	2.9	18
236	Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. <i>Experimental Dermatology</i> , 2019, 28, 35-44.	1.4	15
237	Defining the Molecular Genetics of Dermoscopic Naevus Patterns. <i>Dermatology</i> , 2019, 235, 19-34.	0.9	10
239	Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma. <i>Nature Medicine</i> , 2019, 25, 221-224.	15.2	75
240	Antimelanogenic and Antimigration Properties of the Ethyl Acetate Fraction of <i>Calendula officinalis</i> Flowers on Melanoma Cells. <i>Photochemistry and Photobiology</i> , 2019, 95, 860-866.	1.3	3
241	Interplay between small and long non-coding <sc>RNA</sc>s in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. <i>Molecular Oncology</i> , 2019, 13, 74-98.	2.1	29

#	ARTICLE	IF	CITATIONS
242	Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. <i>Journal of Pathology</i> , 2019, 247, 539-551.	2.1	142
243	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. <i>Pathology</i> , 2019, 51, 39-45.	0.3	25
244	Clinical spectrum of cutaneous melanoma morphology. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 178-188.e3.	0.6	21
245	New Breeding Techniques: Detection and Identification of the Techniques and Derived Products. , 2019, , 320-336.		3
246	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	3.3	83
247	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. <i>Seminars in Cancer Biology</i> , 2019, 54, 14-28.	4.3	51
248	Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1508-1514.	1.0	13
249	Translational genomics of sinonasal cancers. <i>Seminars in Cancer Biology</i> , 2020, 61, 101-109.	4.3	25
250	Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 742-755.	1.4	3
251	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , 2020, 126, 86-97.	2.0	113
252	Genetic alterations in primary melanoma in Taiwan. <i>British Journal of Dermatology</i> , 2020, 182, 1205-1213.	1.4	31
253	From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. <i>Human Pathology</i> , 2020, 95, 149-160.	1.1	6
254	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 149-157.	4.3	30
255	Inhibitors of HSP90 in melanoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 12-28.	2.2	35
256	Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 458-465.	1.5	2
257	Pathology of Sinonasal Tumors and Tumor-Like Lesions. , 2020, , .		9
258	Functional analysis of RPS27 mutations and expression in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 466-479.	1.5	14
259	The role of mechanical stress in the formation of plantar melanoma: a retrospective analysis of 72 chinese patients with plantar melanomas and a meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 90-96.	1.3	6

#	ARTICLE	IF	CITATIONS
260	Mitogen-activated protein kinase dependency in <i>BRAF</i> / <i>RAS</i> wild-type melanoma: A rationale for combination inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 345-357.	1.5	2
261	The mutational landscape of mucosal melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 139-148.	4.3	112
262	The Evolution of Melanoma – Moving beyond Binary Models of Genetic Progression. <i>Journal of Investigative Dermatology</i> , 2020, 140, 291-297.	0.3	7
263	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. <i>American Journal of Surgical Pathology</i> , 2020, 44, 357-367.	2.1	10
264	Ultraviolet radiation and cutaneous melanoma: a historical perspective. <i>Melanoma Research</i> , 2020, 30, 113-125.	0.6	20
265	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63
266	High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities. <i>Targeted Oncology</i> , 2020, 15, 127-138.	1.7	23
267	Differences between acral and nonacral melanoma genomes. <i>British Journal of Dermatology</i> , 2020, 182, 1085-1085.	1.4	0
268	A Versatile ES Cell-Based Melanoma Mouse Modeling Platform. <i>Cancer Research</i> , 2020, 80, 912-921.	0.4	11
269	Targeted molecular therapy: the cancer paradigm. , 2020, , 497-503.		0
270	Tumor genetic heterogeneity analysis of chronic sun-damaged melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 480-489.	1.5	22
271	Defective postreplication repair of UV photoproducts in melanoma: a mutator phenotype. <i>Molecular Oncology</i> , 2020, 14, 5-7.	2.1	1
272	Meta-analysis of functional expression and mutational analysis of c-Met in various cancers. <i>Current Problems in Cancer</i> , 2020, 44, 100515.	1.0	4
273	Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 587-594.	0.9	18
274	Asymmetric repair of UV damage in nucleosomes imposes a DNA strand polarity on somatic mutations in skin cancer. <i>Genome Research</i> , 2020, 30, 12-21.	2.4	25
275	Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 573141.	1.3	63
276	Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. <i>Cancers</i> , 2020, 12, 2799.	1.7	8
277	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. <i>Cancer Letters</i> , 2020, 495, 135-144.	3.2	8

#	ARTICLE	IF	CITATIONS
278	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. <i>Cell</i> , 2020, 183, 197-210.e32.	13.5	141
279	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020, 11, 5259.	5.8	102
280	Telomere Maintenance Associated Mutations in the Genetic Landscape of Gynecological Mucosal Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 1707.	1.3	5
281	Adaptive redox homeostasis in cutaneous melanoma. <i>Redox Biology</i> , 2020, 37, 101753.	3.9	37
282	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17687.	1.6	14
283	Clinical Sequencing of High-Grade Undifferentiated Sarcomas: A Case Series and Report of an Aggressive Primary Cardiac Tumor With Multiple Oncogenic Drivers. <i>JCO Precision Oncology</i> , 2020, 4, 1061-1069.	1.5	1
284	BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103118.	2.0	17
285	The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma. <i>Melanoma Research</i> , 2020, 30, 348-357.	0.6	3
286	Correlation of MET and PD-L1 Expression in Malignant Melanoma. <i>Cancers</i> , 2020, 12, 1847.	1.7	8
287	PRL3-DDX21 Transcriptional Control of Endolysosomal Genes Restricts Melanocyte Stem Cell Differentiation. <i>Developmental Cell</i> , 2020, 54, 317-332.e9.	3.1	30
288	Getting under the skin: The role of CDK4/6 in melanomas. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112531.	2.6	19
289	Cancer mutational signatures representation by large-scale context embedding. <i>Bioinformatics</i> , 2020, 36, i309-i316.	1.8	13
291	Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential. <i>Cancers</i> , 2020, 12, 1901.	1.7	34
292	Spontaneously occurring melanoma in animals and their relevance to human melanoma. <i>Journal of Pathology</i> , 2020, 252, 4-21.	2.1	36
293	Somatic mutational landscapes of adherens junctions and their functional consequences in cutaneous melanoma development. <i>Theranostics</i> , 2020, 10, 12026-12043.	4.6	4
294	Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570654.	1.3	16
295	BRAF: A Two-Faced Janus. <i>Cells</i> , 2020, 9, 2549.	1.8	23
296	Integrated molecular drivers coordinate biological and clinical states in melanoma. <i>Nature Genetics</i> , 2020, 52, 1373-1383.	9.4	36

#	ARTICLE	IF	CITATIONS
297	TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. <i>Annals of Translational Medicine</i> , 2020, 8, 1218-1218.	0.7	7
298	Whole-Genome-Sequenzierung von Schleimhautmelanomen zeigt diverse Treiber und therapeutische Targets auf. <i>Karger Kompass Onkologie</i> , 2020, 7, 119-135.	0.0	0
299	Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 602705.	1.3	20
300	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
301	Identification of an irreversible PPAR α antagonist with potent anticancer activity. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00693.	1.1	7
302	Micro RNAs Promoting Growth and Metastasis in Preclinical <i>In Vivo</i> Models of Subcutaneous Melanoma. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 651-667.	1.0	7
303	3D in vitro cutaneous melanoma models. , 2020, , 287-303.		0
304	Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5231.	1.8	15
305	Targeting telomerase for cancer therapy. <i>Oncogene</i> , 2020, 39, 5811-5824.	2.6	122
306	DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. <i>Nature Genetics</i> , 2020, 52, 958-968.	9.4	76
307	Molecular biology in conjunctival melanoma and the relationship to mucosal melanoma. <i>Acta Ophthalmologica</i> , 2020, 98, 1-27.	0.6	13
308	MicroRNA-21-Enriched Exosomes as Epigenetic Regulators in Melanomagenesis and Melanoma Progression: The Impact of Western Lifestyle Factors. <i>Cancers</i> , 2020, 12, 2111.	1.7	22
309	Attack of the Subclones: Accurate Detection of Mutational Heterogeneity in Bulk DNA from Tumors. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1501-1503.	0.3	1
310	Novel <i>LRRFIP2</i> – <i>RAF1</i> fusion identified in an acral melanoma: A review of the literature on melanocytic proliferations with <i>RAF1</i> fusions and the potential therapeutic implications. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 1181-1186.	0.7	8
311	Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. <i>Cancers</i> , 2020, 12, 1943.	1.7	18
312	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	1.7	22
313	Genetic Alterations in the <i>INK4a/ARF</i> Locus: Effects on Melanoma Development and Progression. <i>Biomolecules</i> , 2020, 10, 1447.	1.8	20
314	Using whole-exome sequencing and protein interaction networks to prioritize candidate genes for germline cutaneous melanoma susceptibility. <i>Scientific Reports</i> , 2020, 10, 17198.	1.6	8

#	ARTICLE	IF	CITATIONS
315	Development of an IFN γ response-related signature for predicting the survival of cutaneous melanoma. <i>Cancer Medicine</i> , 2020, 9, 8186-8201.	1.3	17
316	Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2308-2318.	1.9	14
317	<p>Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7231-7250.	0.9	4
318	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	1.6	25
319	Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases. <i>Nature Communications</i> , 2020, 11, 4306.	5.8	26
320	Improving human cancer therapy through the evaluation of pet dogs. <i>Nature Reviews Cancer</i> , 2020, 20, 727-742.	12.8	102
321	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. <i>Cancer Immunology Research</i> , 2020, 8, 1346-1353.	1.6	13
322	Telomere length set point regulation in human pluripotent stem cells critically depends on the shelterin protein TPP1. <i>Molecular Biology of the Cell</i> , 2020, 31, 2583-2596.	0.9	10
323	Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies. <i>Melanoma Research</i> , 2020, 30, 429-432.	0.6	8
324	Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms. <i>Biology</i> , 2020, 9, 218.	1.3	9
325	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. <i>Melanoma Management</i> , 2020, 7, MMT43.	0.1	7
326	Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. <i>Cancers</i> , 2020, 12, 2359.	1.7	30
327	Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. <i>Cancers</i> , 2020, 12, 2362.	1.7	22
328	Cultivation of Melanoma Cells in vitro on a 3D Scaffold Prepared on the Basis of Gelatin. <i>Cell and Tissue Biology</i> , 2020, 14, 474-480.	0.2	0
329	Spliceosome Mutations in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9546.	1.8	12
330	Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). <i>Diagnostic Pathology</i> , 2020, 15, 143.	0.9	0
331	Atypical UV Photoproducts Induce Non-canonical Mutation Classes Associated with Driver Mutations in Melanoma. <i>Cell Reports</i> , 2020, 33, 108401.	2.9	14
332	The tumor genetics of acral melanoma: What should a dermatologist know?. <i>JAAD International</i> , 2020, 1, 135-147.	1.1	18

#	ARTICLE	IF	CITATIONS
333	KIT Somatic Mutations and Immunohistochemical Expression in Canine Oral Melanoma. <i>Animals</i> , 2020, 10, 2370.	1.0	5
334	Discovery of driver non-coding splice-site-creating mutations in cancer. <i>Nature Communications</i> , 2020, 11, 5573.	5.8	26
335	Applications of Nanomaterials for Theranostics of Melanoma. <i>Journal of Nanotheranostics</i> , 2020, 1, 39-55.	1.7	4
336	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	0.6	62
337	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. <i>Nature Communications</i> , 2020, 11, 2408.	5.8	86
338	Current Molecular Markers of Melanoma and Treatment Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3535.	1.8	45
339	Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 611.	1.3	6
340	Oxidative Stress and Genotoxicity in Melanoma Induction: Impact on Repair Rather Than Formation of DNA Damage?. <i>Photochemistry and Photobiology</i> , 2020, 96, 962-972.	1.3	17
341	Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis. <i>Cancer Medicine</i> , 2020, 9, 7194-7204.	1.3	8
342	EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2442-2454.e5.	0.3	46
343	Circular RNAs: new genetic tools in melanoma. <i>Biomarkers in Medicine</i> , 2020, 14, 563-571.	0.6	16
344	Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma. <i>Nature Cancer</i> , 2020, 1, 635-652.	5.7	26
345	Pervasive lesion segregation shapes cancer genome evolution. <i>Nature</i> , 2020, 583, 265-270.	13.7	36
346	Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092202.	1.4	29
347	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. <i>Modern Pathology</i> , 2020, 33, 2397-2406.	2.9	16
348	Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. <i>Annals of Oncology</i> , 2020, 31, 1198-1206.	0.6	96
349	Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. <i>Cancers</i> , 2020, 12, 1468.	1.7	14
350	Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan. <i>Frontiers in Oncology</i> , 2020, 10, 905.	1.3	14

#	ARTICLE	IF	CITATIONS
351	MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients. <i>Clinical and Experimental Medicine</i> , 2020, 20, 299-311.	1.9	7
352	Whole genome resequencing of the Iranian native dogs and wolves to unravel variome during dog domestication. <i>BMC Genomics</i> , 2020, 21, 207.	1.2	6
353	Mutation Signatures in Melanocytic Nevi Reveal Characteristics of Defective DNA Repair. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2093-2096.e2.	0.3	7
354	The Solo Play of TERT Promoter Mutations. <i>Cells</i> , 2020, 9, 749.	1.8	27
355	Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2301-2312.	3.3	47
356	Comprehensive analysis of indels in whole-genome microsatellite regions and microsatellite instability across 21 cancer types. <i>Genome Research</i> , 2020, 30, 334-346.	2.4	56
357	TERT promoter mutations and telomeres during tumorigenesis. <i>Current Opinion in Genetics and Development</i> , 2020, 60, 56-62.	1.5	50
358	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. <i>Cancers</i> , 2020, 12, 540.	1.7	55
359	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. <i>Modern Pathology</i> , 2020, 33, 1466-1474.	2.9	28
360	Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy. <i>Cancer Research</i> , 2020, 80, 1942-1956.	0.4	25
361	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 113.	1.6	52
362	Targeted Therapy in Melanoma and Mechanisms of Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4576.	1.8	107
363	A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 1056.	1.3	5
364	PD-1 blockade in Japanese patients with acral lentiginous melanoma. <i>Annals of Oncology</i> , 2020, 31, 1106-1108.	0.6	1
365	Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns. <i>Science Advances</i> , 2020, 6, .	4.7	53
366	An NRAS mutation in primary malignant melanoma of the lung: a case report. <i>Diagnostic Pathology</i> , 2020, 15, 11.	0.9	7
367	Telomerase: Key regulator of inflammation and cancer. <i>Pharmacological Research</i> , 2020, 155, 104726.	3.1	35
368	Characterizations of Gene Alterations in Melanoma Patients from Chinese Population. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	9

#	ARTICLE	IF	CITATIONS
369	BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 179-191.	2.2	8
370	Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives. <i>Current Treatment Options in Oncology</i> , 2020, 21, 19.	1.3	3
371	Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 972-977.	1.0	20
372	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. <i>Nature Cancer</i> , 2020, 1, 197-209.	5.7	30
373	Subungual melanoma: the experience of a Greek melanoma reference centre from 2003 to 2018. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e231-e234.	1.3	6
374	Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma. <i>Journal of Dermatological Science</i> , 2020, 97, 172-178.	1.0	4
375	WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5â€“MDM2â€“p53 pathway. <i>Oncogene</i> , 2020, 39, 2741-2755.	2.6	17
376	Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 601-611.	1.5	15
377	Personalized medicine. Precision medicine: PART B multifactorial diseases, genes, environments, interactions. , 2020, , 259-290.		0
378	A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. <i>Nature Communications</i> , 2020, 11, 728.	5.8	140
379	The repertoire of mutational signatures in human cancer. <i>Nature</i> , 2020, 578, 94-101.	13.7	2,104
380	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	13.7	1,966
381	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53
382	Novel mutations identified by whole-exome sequencing in acral melanoma. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1792-1794.	0.6	8
383	Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. <i>Nature Medicine</i> , 2020, 26, 781-791.	15.2	75
384	Building avatar armies with fish and flies. <i>Lab Animal</i> , 2020, 49, 101-104.	0.2	2
385	Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 960.	1.7	25
386	Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy. <i>Case Reports in Oncology</i> , 2020, 13, 271-275.	0.3	3

#	ARTICLE	IF	CITATIONS
387	p16 Range of expression in dermal predominant benign epithelioid and spindled nevi and melanoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 815-823.	0.7	14
388	Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine. <i>Clinical Cancer Research</i> , 2020, 26, 3408-3419.	3.2	35
389	Molecular profiling of driver events in metastatic uveal melanoma. <i>Nature Communications</i> , 2020, 11, 1894.	5.8	108
390	An alternative pathway for cellular protection in BRAF inhibitor resistance in aggressive melanoma type skin cancer. <i>Chemico-Biological Interactions</i> , 2020, 323, 109061.	1.7	6
391	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4250-4259.	3.2	104
392	Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. <i>BMC Cancer</i> , 2020, 20, 291.	1.1	20
393	Precision in cancer pharmacogenomics. <i>Pharmacogenomics</i> , 2020, 21, 311-316.	0.6	1
394	Molecular subtype, biological sex and age shape melanoma tumour evolution. <i>British Journal of Dermatology</i> , 2021, 184, 328-337.	1.4	13
395	Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 59-71.	1.5	65
396	Genomic profiling of late-onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 396-402.	1.3	2
397	Map3k1 Loss Cooperates with Braf to Drive Melanomagenesis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 221-225.e6.	0.3	3
398	Immunotherapy for advanced melanoma: current situation in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 3-9.	0.6	11
399	Cyclic adenosine monophosphate (cAMP) signaling in melanocyte pigmentation and melanomagenesis. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 28-43.	1.5	21
400	Prognostic significance of acral lentiginous histologic type in T1 melanoma. <i>Modern Pathology</i> , 2021, 34, 572-583.	2.9	8
401	Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma. <i>Modern Pathology</i> , 2021, 34, 141-160.	2.9	9
402	Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus. <i>Histopathology</i> , 2021, 78, 240-251.	1.6	9
403	Trends in the prognosis of metastatic melanoma in the era of targeted therapy and immunotherapy: A single-institution survey in Japan. <i>Journal of Dermatology</i> , 2021, 48, 75-79.	0.6	3
404	Melanomas and stress patterns on the foot: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 256-258.	0.6	5

#	ARTICLE	IF	CITATIONS
405	Extracutaneous Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 85-98.	0.9	3
406	The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin. Annals of Oncology, 2021, 32, 412-421.	0.6	29
407	Making a melanoma: Molecular and cellular changes underlying melanoma initiation. Pigment Cell and Melanoma Research, 2021, 34, 280-287.	1.5	3
408	Advanced Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 111-128.	0.9	5
409	Identification of vital genes and pathways associated with mucosal melanoma in Chinese. Annals of Diagnostic Pathology, 2021, 50, 151648.	0.6	1
411	Biology of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 29-56.	0.9	40
412	Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. Translational Oncology, 2021, 14, 100921.	1.7	34
413	The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell and Melanoma Research, 2021, 34, 529-549.	1.5	21
414	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. Advanced Therapeutics, 2021, 4, 2000147.	1.6	2
415	Molecular Landscape Profile of Melanoma. , 2021, , 31-55.		0
416	Regional lymph node infiltration and thick lesions are associated with poor prognosis in high-risk resected melanomas: A retrospective cohort study. Annals of Medicine and Surgery, 2021, 61, 132-138.	0.5	2
418	Multi-Dimensional Biomarkers for the Personalized Treatment of Melanoma. , 2021, , 361-364.		1
419	Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?. Journal of Clinical Medicine, 2021, 10, 478.	1.0	12
420	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. Nature Communications, 2021, 12, 259.	5.8	27
421	Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion. Frontiers in Surgery, 2020, 7, 616174.	0.6	7
422	Genomic Landscapes of Acral Melanomas in East Asia. Cancer Genomics and Proteomics, 2021, 18, 83-92.	1.0	6
423	Skin Cancer: Molecular Biomarker for Diagnosis, Prognosis, Prevention, and Targeted Therapy. , 2021, , 101-130.		0
424	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. , 2021, 9, e001642.		28

#	ARTICLE	IF	CITATIONS
425	PLEKHA4 Promotes Wnt/ β -Catenin Signaling-Mediated G1/S Transition and Proliferation in Melanoma. <i>Cancer Research</i> , 2021, 81, 2029-2043.	0.4	13
426	Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma. <i>Cancers</i> , 2021, 13, 731.	1.7	12
427	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	1.7	41
428	Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. <i>Experimental Dermatology</i> , 2022, 31, 13-30.	1.4	14
429	From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past. <i>Frontiers in Immunology</i> , 2021, 12, 623639.	2.2	22
430	On Naevi and Melanomas: Two Sides of the Same Coin?. <i>Frontiers in Medicine</i> , 2021, 8, 635316.	1.2	6
432	Female Genital Tract Melanoma: 10 Years of Experience at a Single Tertiary Center. <i>Journal of Lower Genital Tract Disease</i> , 2021, 25, 142-145.	0.9	3
433	PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. <i>Npj Precision Oncology</i> , 2021, 5, 10.	2.3	57
434	A unified haplotype-based method for accurate and comprehensive variant calling. <i>Nature Biotechnology</i> , 2021, 39, 885-892.	9.4	56
435	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021, 12, 1434.	5.8	46
436	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021, 10, 2627-2635.	1.3	5
437	MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8. <i>Scientific Reports</i> , 2021, 11, 5660.	1.6	4
438	Review on Canine Oral Melanoma: An Undervalued Authentic Genetic Model of Human Oral Melanoma?. <i>Veterinary Pathology</i> , 2021, 58, 881-889.	0.8	16
439	Identification of bacteria-derived HLA-bound peptides in melanoma. <i>Nature</i> , 2021, 592, 138-143.	13.7	187
440	Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma. <i>Molecular Cancer Research</i> , 2021, 19, 991-1004.	1.5	19
441	Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. <i>Journal of Dermatology</i> , 2021, 48, 592-599.	0.6	10
442	Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 867-869.	0.8	4
443	Bioresorbable Scaffolds with Biocatalytic Chemotherapy and In Situ Microenvironment Modulation for Postoperative Tissue Repair. <i>Advanced Functional Materials</i> , 2021, 31, 2008732.	7.8	22

#	ARTICLE	IF	CITATIONS
445	PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK. <i>Cell Reports</i> , 2021, 34, 108928.	2.9	17
446	Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3228.	1.8	5
447	The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. <i>Nature Communications</i> , 2021, 12, 1808.	5.8	90
448	Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX. <i>Nature Communications</i> , 2021, 12, 1552.	5.8	24
450	Resistance to Molecularly Targeted Therapies in Melanoma. <i>Cancers</i> , 2021, 13, 1115.	1.7	36
451	The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299.	1.3	15
452	The RIT1 C-terminus associates with lipid bilayers via charge complementarity. <i>Computational Biology and Chemistry</i> , 2021, 91, 107437.	1.1	6
453	Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients. <i>Molecular Cancer Research</i> , 2021, 19, 950-956.	1.5	19
454	Advances in Targeting Cutaneous Melanoma. <i>Cancers</i> , 2021, 13, 2090.	1.7	19
455	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021, 16, e0248097.	1.1	5
457	Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy†. <i>Annals of Oncology</i> , 2021, 32, 500-511.	0.6	9
458	The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI). <i>International Journal of Molecular Sciences</i> , 2021, 22, 3826.	1.8	12
459	Wavelengths and temporal effects on the response of mammalian cells to UV radiation: Limitations of action spectra illustrated by genotoxicity. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2021, 217, 112169.	1.7	2
460	RTK Inhibitors in Melanoma: From Bench to Bedside. <i>Cancers</i> , 2021, 13, 1685.	1.7	26
462	Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice. <i>Gynecologic Oncology</i> , 2021, 161, 202-210.	0.6	8
463	Sunglasses to hide behind may also prevent melanoma of the eyes. <i>British Journal of Cancer</i> , 2021, 125, 470-472.	2.9	2
464	Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development. <i>Cancers</i> , 2021, 13, 1762.	1.7	5
465	Pigmentation Levels Affect Melanoma Responses to <i>Coriolus versicolor</i> Extract and Play a Crucial Role in Melanoma-Mononuclear Cell Crosstalk. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5735.	1.8	12

#	ARTICLE	IF	CITATIONS
466	Daily Lifestyle and Cutaneous Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5227.	1.8	13
467	Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 639085.	1.3	6
468	BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma. <i>Cancers</i> , 2021, 13, 2393.	1.7	8
469	Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies. <i>Frontiers in Oncology</i> , 2021, 11, 635488.	1.3	36
470	Observation policy for sentinel node metastasis of melanoma: Comparative study with completion lymph node dissection in Japanese patients. <i>Journal of Dermatology</i> , 2021, 48, 1221-1228.	0.6	1
472	Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5115.	1.8	8
473	Genetic alteration of Chinese patients with rectal mucosal melanoma. <i>BMC Cancer</i> , 2021, 21, 623.	1.1	2
474	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	7.7	90
475	Who's Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. <i>Cancers</i> , 2021, 13, 2725.	1.7	7
476	Regulation of the Phosphoinositide Code by Phosphorylation of Membrane Readers. <i>Cells</i> , 2021, 10, 1205.	1.8	8
477	Clinical significance of CCNE1 copy number gain in acral melanoma patients. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 352-357.	0.6	1
478	Enhancer release and retargeting activates disease-susceptibility genes. <i>Nature</i> , 2021, 595, 735-740.	13.7	76
479	CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. <i>Cells</i> , 2021, 10, 1334.	1.8	31
480	Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases. <i>Frontiers in Oncology</i> , 2021, 11, 668505.	1.3	4
481	The genetic and epigenetic basis of distinct melanoma types. <i>Journal of Dermatology</i> , 2021, 48, 925-939.	0.6	6
482	Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors. <i>Cancer Science</i> , 2021, 112, 3163-3172.	1.7	11
483	The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma. <i>Molecular Oncology</i> , 2022, 16, 565-593.	2.1	11
485	Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract. <i>BMC Cancer</i> , 2021, 21, 677.	1.1	6

#	ARTICLE	IF	CITATIONS
486	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	1.7	9
487	Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 675873.	1.3	7
488	The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma. <i>Modern Pathology</i> , 2021, 34, 2009-2019.	2.9	18
490	Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study. <i>Cancers</i> , 2021, 13, 3101.	1.7	5
491	Rejection of benign melanocytic nevi by nevus-resident CD4 ⁺ T cells. <i>Science Advances</i> , 2021, 7, .	4.7	6
492	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. <i>Cancer Cell</i> , 2021, 39, 845-865.e7.	7.7	503
493	Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells. <i>Communications Biology</i> , 2021, 4, 672.	2.0	7
494	Evolving treatments and future therapeutic targets in desmoplastic melanoma. <i>Melanoma Management</i> , 2021, 8, MMT56.	0.1	0
495	Melanoma in Singapore: A 20-year review of disease and treatment outcomes. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 456-466.	0.2	4
496	Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. <i>Frontiers in Immunology</i> , 2021, 12, 680407.	2.2	68
497	Learning mutational signatures and their multidimensional genomic properties with TensorSignatures. <i>Nature Communications</i> , 2021, 12, 3628.	5.8	30
498	Evaluation of Crizotinib Treatment in a Patient With Unresectable <i>GOPC-ROS1</i> Fusion Agminated Spitz Nevi. <i>JAMA Dermatology</i> , 2021, 157, 836-841.	2.0	9
499	Coupling between Sequence-Mediated Nucleosome Organization and Genome Evolution. <i>Genes</i> , 2021, 12, 851.	1.0	5
500	Mucosal Melanoma. <i>Surgical Pathology Clinics</i> , 2021, 14, 293-307.	0.7	1
501	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. <i>Pathology</i> , 2021, 53, 830-835.	0.3	7
502	Establishment of cultured primary acral melanoma cells and animal models for Chinese patients. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 1131-1137.	1.5	6
503	Melanoma genomics: a state-of-the-art review of practical clinical applications*. <i>British Journal of Dermatology</i> , 2021, 185, 272-281.	1.4	12
504	CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort. <i>Diagnostic Pathology</i> , 2021, 16, 60.	0.9	3

#	ARTICLE	IF	CITATIONS
505	Targeted sequencing of localized acral melanoma in Korean patients identified recurrent CCND1 amplification. <i>International Journal of Dermatology</i> , 2021, , .	0.5	0
506	More than just acral melanoma: the controversies of defining the disease. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 531-541.	1.3	10
507	Interpretable deep learning uncovers cellular properties in label-free live cell images that are predictive of highly metastatic melanoma. <i>Cell Systems</i> , 2021, 12, 733-747.e6.	2.9	48
508	Histopathologic classification and prognostic factors of melanoma: a 2021 update. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 300-321.	0.1	30
509	Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine. <i>Cancers</i> , 2021, 13, 3836.	1.7	10
510	Evolution of the Clinical, Dermoscopic and Pathologic Diagnosis of Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021163S.	0.5	9
511	Transcription-coupled nucleotide excision repair: New insights revealed by genomic approaches. <i>DNA Repair</i> , 2021, 103, 103126.	1.3	22
513	Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 691032.	2.2	10
514	Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes. <i>Human Mutation</i> , 2021, 42, 1187-1207.	1.1	5
515	Primary melanoma of the anorectal region: clinical and histopathological review of 17 cases. A retrospective cohort study. <i>Colorectal Disease</i> , 2021, 23, 2706-2713.	0.7	6
516	Squaring the circle: circRNAs in melanoma. <i>Oncogene</i> , 2021, 40, 5559-5566.	2.6	10
517	Genome-wide profiles of UV lesion susceptibility, repair, and mutagenic potential in melanoma. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2021, 823, 111758.	0.4	4
518	Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma. <i>Cancers</i> , 2021, 13, 3874.	1.7	9
519	The Genetics of Uveal Melanoma: Overview and Clinical Relevance. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2021, 238, 773-780.	0.3	7
520	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 281-294.	0.4	4
521	Biochemical and photochemical mechanisms that produce different UV-induced mutation spectra. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2021, 823, 111762.	0.4	6
522	Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 702287.	1.3	31
523	Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. <i>Oncogene</i> , 2021, 40, 5718-5729.	2.6	1

#	ARTICLE	IF	CITATIONS
524	Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. <i>Cells</i> , 2021, 10, 2216.	1.8	8
525	Characteristics of circRNA and its approach as diagnostic tool in melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1079-1094.	1.5	1
526	Dedifferentiated melanoma with MDM2 gene amplification mimicking dedifferentiated liposarcoma. <i>Pathology</i> , 2022, 54, 371-374.	0.3	3
527	The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia. <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, .	0.7	2
528	Stem cell spreading dynamics intrinsically differentiate acral melanomas from nevi. <i>Cell Reports</i> , 2021, 36, 109492.	2.9	8
529	Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis. <i>Melanoma Research</i> , 2021, 31, 482-486.	0.6	9
530	Occurrence, functionality and abundance of the <i>TERT</i> promoter mutations. <i>International Journal of Cancer</i> , 2021, 149, 1852-1862.	2.3	13
532	Next-Generation Immunotherapy Approaches in Melanoma. <i>Current Oncology Reports</i> , 2021, 23, 116.	1.8	3
533	Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma. <i>Trends in Cancer</i> , 2021, 7, 671-681.	3.8	11
535	Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect. <i>Cancers</i> , 2021, 13, 3948.	1.7	9
536	Acral lentiginous melanoma—Population, treatment, and survival using the NCDB from 2004 to 2015. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 1049-1061.	1.5	8
537	Human melanocyte development and melanoma dedifferentiation at single-cell resolution. <i>Nature Cell Biology</i> , 2021, 23, 1035-1047.	4.6	59
538	Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. <i>Journal of Pathology</i> , 2022, 256, 61-70.	2.1	12
539	CTCF binding modulates UV damage formation to promote mutation hot spots in melanoma. <i>EMBO Journal</i> , 2021, 40, e107795.	3.5	19
540	NRAS mutant melanoma: Towards better therapies. <i>Cancer Treatment Reviews</i> , 2021, 99, 102238.	3.4	56
541	Intragenic <i>NF1</i> deletions in sinonasal mucosal malignant melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 88-96.	1.5	2
542	<i>TERT</i> ; Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy. <i>Dermatology</i> , 2022, 238, 507-516.	0.9	0
543	A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2238-2249.e12.	0.3	7

#	ARTICLE	IF	CITATIONS
544	Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases. <i>Melanoma Research</i> , 2021, 31, 575-578.	0.6	5
545	MicroRNA Isoforms Contribution to Melanoma Pathogenesis. <i>Non-coding RNA</i> , 2021, 7, 63.	1.3	6
546	PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?. <i>Cancers</i> , 2021, 13, 4520.	1.7	8
547	Molecular Markers and Targets in Melanoma. <i>Cells</i> , 2021, 10, 2320.	1.8	72
548	Subungual Melanoma: A Single Institution Experience. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 57.	1.3	3
549	mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. <i>Vaccines</i> , 2021, 9, 1060.	2.1	39
550	Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 495-503.	0.6	2
552	Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-Like Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2470-2479.	0.3	1
553	Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study. <i>European Journal of Cancer</i> , 2021, 157, 361-372.	1.3	24
554	Melanoma-derived induced pluripotent stem cells. , 2021, , 191-219.		2
555	Identification of Genetic Variants and de novo Mutations Based on NGS. <i>Learning Materials in Biosciences</i> , 2021, , 123-142.	0.2	0
556	<i>PTEN</i> Promoter Hypermethylation Is Associated with Breslow Thickness in Acral Melanoma on the Heel, Forefoot, and Hallux. <i>Annals of Dermatology</i> , 2021, 33, 18.	0.3	0
557	Survival and Prognostic Nomogram for Primary Gastrointestinal Melanoma (PGIM): A Population-based Study. <i>Anticancer Research</i> , 2021, 41, 967-974.	0.5	5
559	Cul4b Promotes Progression of Malignant Cutaneous Melanoma Patients by Regulating CDKN2A. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 254, 33-39.	0.5	1
560	Frequency of Trauma, Physical Stress, and Occupation in Acral Melanoma: Analysis of 313 Acral Melanoma Patients in Korea. <i>Annals of Dermatology</i> , 2021, 33, 228.	0.3	9
562	Genome-Wide Mapping of UV-Induced DNA Damage with CPD-Seq. <i>Methods in Molecular Biology</i> , 2020, 2175, 79-94.	0.4	15
563	Molecular Pathology and Genomics of Melanoma. , 2020, , 381-422.		1
564	Clinical Epidemiology of Melanoma. , 2020, , 425-449.		5

#	ARTICLE	IF	CITATIONS
565	Classification and Histopathology of Melanoma. , 2020, , 317-379.		1
566	Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. , 2020, , 1301-1335.		2
567	Clinical Presentations of Melanoma. , 2020, , 107-144.		2
568	Molecular Pathology and Genomics of Melanoma. , 2019, , 1-42.		2
569	Systemic Therapy for Mucosal, Acral and Uveal Melanoma. , 2019, , 1-37.		1
570	KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. American Journal of Clinical Dermatology, 2019, 20, 315-323.	3.3	64
571	Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma. Journal of Surgical Research, 2020, 254, 147-153.	0.8	3
572	Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 2021, 12, 1137.	5.8	33
573	The <i>TERT</i> copy number gain is sensitive to telomerase inhibitors in human melanoma. Clinical Science, 2020, 134, 193-205.	1.8	15
574	<i>SPRED1</i> deletion confers resistance to MAPK inhibition in melanoma. Journal of Experimental Medicine, 2021, 218, .	4.2	19
575	Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Research, 2020, 30, 562-573.	0.6	18
576	MAP2K1-Mutated Melanocytic Neoplasms With a SPARK-Like Morphology. American Journal of Dermatopathology, 2021, 43, 412-417.	0.3	14
592	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	3.2	6
593	Unbiased Detection of Driver Mutations in Extramammary Paget Disease. Clinical Cancer Research, 2021, 27, 1756-1765.	3.2	24
594	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. Journal of Clinical Investigation, 2019, 129, 1940-1945.	3.9	37
595	Complete epigenomic and genomic analysis of transcriptome modulation within skin cutaneous melanoma. Medical Science Monitor, 2020, 26, e921133.	0.5	12
596	Genomic and transcriptomic landscape of conjunctival melanoma. PLoS Genetics, 2020, 16, e1009201.	1.5	18
597	Sensitive droplet digital PCR method for detection of <i>TERT</i> promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 2017, 8, 78890-78900.	0.8	44

#	ARTICLE	IF	CITATIONS
598	Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations. <i>Oncotarget</i> , 2018, 9, 5691-5702.	0.8	9
599	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. <i>Oncotarget</i> , 2019, 10, 930-941.	0.8	31
600	Mutation profile of primary subungual melanomas in Caucasians. <i>Oncotarget</i> , 2020, 11, 2404-2413.	0.8	13
601	Melanoma Genomics. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00138.	0.6	11
602	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. <i>Deutsches A&#x0308;rzteblatt International</i> , 2019, 116, 497-504.	0.6	15
603	Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 524700.	1.3	17
604	Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. , 2020, 1, 101-108.		4
605	Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E. <i>Endocrinology and Metabolism</i> , 2020, 35, 515-525.	1.3	10
606	Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. <i>Cancer Research and Treatment</i> , 2020, 52, 730-738.	1.3	7
607	Accelerating cancer without mutations. <i>ELife</i> , 2019, 8, .	2.8	1
608	Exploring the classification of cancer cell lines from multiple omic views. <i>PeerJ</i> , 2020, 8, e9440.	0.9	6
609	Oncogenic Alterations Reveal Key Strategies for Precision Oncology in Melanoma Treatment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
610	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
611	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021, 12, 1629.	1.0	8
612	Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1413-1424.e6.	0.3	3
613	Acral Melanoma. , 2018, , 1-28.		0
617	Clinical Presentations of Melanoma. , 2019, , 1-38.		0
618	Clinical Epidemiology of Melanoma. , 2019, , 1-25.		0

#	ARTICLE	IF	CITATIONS
619	Molecular Epidemiology of Melanoma. , 2019, , 1-19.		0
620	Genomic Applications in Melanoma. , 2019, , 509-540.		0
621	Classification and Histopathology of Melanoma. , 2019, , 1-64.		0
622	Uveal Metastatic Tumors. , 2019, , 403-421.		1
624	Molecular Diagnostics in Melanocytic Neoplasia. , 2019, , 1-22.		0
625	Desmoplastic Melanoma. , 2019, , 1-13.		0
626	Dysregulation of Cis-Regulatory Elements in Cancer. , 2019, , 173-192.		1
631	Treatment of Occupational Skin Cancer. , 2020, , 1483-1492.		0
632	Molecular Pathology of Sinonasal Tumors. , 2020, , 19-35.		0
634	Biological and immunological characteristics of melanoma subtypes predominant in Japan. Skin Cancer, 2020, 35, 92-97.	0.1	0
635	Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression. Molecular and Clinical Oncology, 2020, 13, 175-178.	0.4	2
636	RAF1 Gene Fusions as a Possible Driver Mechanism in Rare BAP1-Inactivated Melanocytic Tumors: A Report of 2 Cases. American Journal of Dermatopathology, 2020, 42, 961-966.	0.3	15
637	MR imaging characteristics of uveal melanoma with histopathological validation. Neuroradiology, 2022, 64, 171-184.	1.1	16
638	Bioinformatic and Machine Learning Applications in Melanoma Risk Assessment and Prognosis: A Literature Review. Genes, 2021, 12, 1751.	1.0	7
639	Multimodality Imaging and Genetics of Primary Mucosal Melanomas and Response to Treatment. Radiographics, 2021, 41, 1954-1972.	1.4	2
640	Modern combined targeted and immunotherapy of metastatic skin melanoma. Meditsinskiy Sovet, 2020, , 54-61.	0.1	1
642	Surgical Resection Margin for T3-T4 Primary Acral Melanoma—A Multicenter Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
643	Acral Lentiginous Melanoma. , 2020, , 897-924.		0

#	ARTICLE	IF	CITATIONS
644	...ç--«ãfã,Sãffã,ãfã,ãfã³ãf^é~»ã³ã%ãä½œç”æ©ÿã°ã·ãfã,ã,ããfžãf¼ã,«ãf¼. Skin Cancer, 2021, 36, 133-138.	0.1	0
645	Molecular Epidemiology of Melanoma. , 2020, , 451-469.		0
648	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?. Frontiers in Oncology, 2021, 11, 775100.	1.3	6
649	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. European Journal of Cancer, 2021, 159, 113-124.	1.3	13
652	NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy. Current Gene Therapy, 2020, 20, 100-108.	0.9	8
654	The Influences of Omega-3 Polyunsaturated Fatty Acids on the Development of Skin Cancers. Diagnostics, 2021, 11, 2149.	1.3	6
655	Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor. Oncogene, 2022, 41, 732-744.	2.6	12
656	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers, 2021, 13, 5847.	1.7	16
657	Transcriptional profile and chromatin accessibility in zebrafish melanocytes and melanoma tumors. G3: Genes, Genomes, Genetics, 2022, 12, .	0.8	3
658	Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.1	1
659	Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants. Frontiers in Oncology, 2021, 11, 752579.	1.3	1
660	Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. Cancers, 2021, 13, 6061.	1.7	5
661	Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open, 2021, 6, 100325.	2.0	24
663	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis. Cancer Control, 2021, 28, 107327482110535.	0.7	7
664	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. JCO Precision Oncology, 2021, 5, 1821-1829.	1.5	17
665	Epigenetics in the Diagnosis and Therapy of Malignant Melanoma. International Journal of Molecular Sciences, 2022, 23, 1531.	1.8	7
666	Diagnosis and treatment of nail melanoma: a review of the clinicopathologic, dermoscopic, and genetic characteristics. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 651-660.	1.3	8
667	Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource. Genome Biology, 2022, 23, 35.	3.8	38

#	ARTICLE	IF	CITATIONS
668	Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets. <i>Cancers</i> , 2022, 14, 276.	1.7	3
670	Retinoblastoma protein regulates carcinogen susceptibility at heterochromatic cancer driver loci. <i>Life Science Alliance</i> , 2022, 5, e202101134.	1.3	4
671	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 785526.	2.2	6
672	Multitomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	7.7	64
673	Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 703821.	2.2	2
674	qmotif: determination of telomere content from whole-genome sequence data. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	5
675	Structural insights into the interactions and epigenetic functions of human nucleic acid repair protein ALKBH6. <i>Journal of Biological Chemistry</i> , 2022, 298, 101671.	1.6	10
676	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
677	Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival. <i>Gynecologic Oncology</i> , 2022, 165, 53-59.	0.6	1
678	Qa-1b functions as an oncogenic factor in mouse melanoma cells. <i>Journal of Dermatological Science</i> , 2022, 105, 159-169.	1.0	2
679	Characterisation of the spectrum and genetic dependence of collateral mutations induced by translesion DNA synthesis. <i>PLoS Genetics</i> , 2022, 18, e1010051.	1.5	7
680	A Novel Ferroptosis-Related lncRNA Prognostic Model and Immune Infiltration Features in Skin Cutaneous Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 790047.	1.8	5
681	Adipocyte Extracellular Vesicles Decrease p16INK4A in Melanoma: An Additional Link between Obesity and Cancer. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2488-2498.e8.	0.3	3
682	Update on classification of melanocytic tumors and the role of immunohistochemistry and molecular techniques. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 248-256.	1.0	4
683	The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 982-988.	3.6	21
684	Differential Gene Expression and Pathway Analysis in Melanoma Cell Lines Following MET and PD-L1 Downregulation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
685	Cutaneous malignant melanoma incidence is strongly associated with European depigmented skin type regardless of ambient ultraviolet radiation levels: evidence from Worldwide population-based data. <i>AIMS Public Health</i> , 2022, 9, 378-402.	1.1	6
686	Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. <i>Nature Communications</i> , 2022, 13, 898.	5.8	19

#	ARTICLE	IF	CITATIONS
687	RAS pathway regulation in melanoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	11
688	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 839901.	2.2	1
689	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
691	Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study. <i>Genes</i> , 2022, 13, 545.	1.0	8
692	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
693	Cell position matters in tumour development. <i>Nature</i> , 2022, , .	13.7	0
694	Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. <i>Practical Radiation Oncology</i> , 2022, 12, 437-445.	1.1	5
696	A Bâ€cell or a key player? The different roles of Bâ€cells and antibodies in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 303-319.	1.5	5
697	Systematic review and metaâ€analysis of genomic alterations in acral melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 369-386.	1.5	6
698	Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1332-1352.	1.0	4
699	TRPM1 promotes tumor progression in acral melanoma by activating the Ca ²⁺ /CaMKIIÎ´/AKT pathway. <i>Journal of Advanced Research</i> , 2022, , .	4.4	5
700	Anatomic position determines oncogenic specificity in melanoma. <i>Nature</i> , 2022, 604, 354-361.	13.7	44
701	Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. <i>Pathology</i> , 2022, 54, 533-540.	0.3	3
702	Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations. <i>Clinical Cancer Research</i> , 2022, 28, 2690-2703.	3.2	10
703	Choroidal melanoma with synchronous Fuchsâ€™ adenoma and novel ATRX mutation. <i>International Journal of Retina and Vitreous</i> , 2022, 8, 24.	0.9	1
704	Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4044.	1.8	9
705	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. <i>Cell Reports</i> , 2022, 39, 110634.	2.9	10
706	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	2.2	2

#	ARTICLE	IF	CITATIONS
707	Bioinformatic Challenges Detecting Genetic Variation in Precision Medicine Programs. <i>Frontiers in Medicine</i> , 2022, 9, 806696.	1.2	3
708	Management of Head and Neck Mucosal Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 299-314.	0.4	2
709	OrienX010, an oncolytic virus, in patients with unresectable stage III-IV melanoma: a phase Ib study. , 2022, 10, e004307.		13
710	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 167, 70-80.	1.3	19
711	Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers. <i>Cancers</i> , 2021, 13, 6180.	1.7	8
712	Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis. <i>Cancers</i> , 2022, 14, 123.	1.7	11
713	Gene mutations and clinical prognosis of mucosal melanoma in different locations of head and neck. <i>Acta Oto-Laryngologica</i> , 2022, 142, 94-99.	0.3	0
714	Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma. <i>ELife</i> , 2021, 10, .	2.8	5
715	Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy. <i>Cancers</i> , 2021, 13, 6217.	1.7	9
716	Novel insights into the BAP1-inactivated melanocytic tumor. <i>Modern Pathology</i> , 2022, 35, 664-675.	2.9	7
717	Identification of distinct genomic features reveals frequent somatic AHNK and PTEN mutations predominantly in primary malignant melanoma presenting in the ureter. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 930-943.	0.6	3
718	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Frontiers in Oncology</i> , 2022, 12, 820510.	1.3	2
719	Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 777775.	1.6	3
759	Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2733-2743.e9.	0.3	7
760	Weight-bearing activity impairs nuclear membrane and genome integrity via YAP activation in plantar melanoma. <i>Nature Communications</i> , 2022, 13, 2214.	5.8	11
761	Somatic Mutation Profiling in Head and Neck Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1833-1842.	1.8	6
762	Prognostic factors and incidence of primary mucosal melanoma: a population-based study in France. <i>European Journal of Dermatology</i> , 2018, 28, 654-660.	0.3	5
763	Melanoma: An immunotherapy Journey from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.2	0

#	ARTICLE	IF	CITATIONS
765	Efficacy Comparison between Anti-PD-1 Antibody Monotherapy and Anti-PD-1 Plus Anti-CTLA-4 Combination Therapy as First-Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients. SSRN Electronic Journal, 0, , .	0.4	0
766	Exploring Tumor Immune Microenvironment and Its Associations With Molecular Characteristics in Melanoma. <i>Frontiers in Oncology</i> , 2022, 12, 821578.	1.3	3
767	Evolving Treatment Approaches to Mucosal Melanoma. <i>Current Oncology Reports</i> , 2022, 24, 1261-1271.	1.8	7
768	Features of Skin Cancer in Black Individuals: A Single-Institution Retrospective Cohort Study. <i>Dermatology Practical and Conceptual</i> , 0, , e2022075.	0.5	1
769	FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 170.	3.5	1
770	Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapyâ€”Present State and Perspectives. <i>Cancers</i> , 2022, 14, 2315.	1.7	7
771	Enhanced Expression of p21 Promotes Sensitivity of Melanoma Cells Towards Targeted Therapies. <i>Experimental Dermatology</i> , 2022, , .	1.4	1
772	The future of targeted kinase inhibitors in melanoma. , 2022, 239, 108200.		17
773	The significance of intratumoural <sc>CD163</sc> ⁺ macrophages in oral malignant melanoma: A preliminary study. <i>Oral Diseases</i> , 2022, , .	1.5	0
774	Necroptosis-associated classification combined with tumor microenvironment characteristic analysis of cutaneous melanoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
776	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.3	6
777	Alterations in transcriptional networks in cancer: the role of noncoding somatic driver mutations. <i>Current Opinion in Genetics and Development</i> , 2022, 75, 101919.	1.5	2
779	Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5911.	1.8	14
780	Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2022, 14, .	3.6	24
781	Candidate therapeutic agents in a newly established triple wildâ€”type mucosal melanoma cell line. <i>Cancer Communications</i> , 2022, 42, 627-647.	3.7	5
782	Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
783	Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00756.	0.6	8
784	Research Progress of Cell Lineage Tracing and Single-Cell Sequencing Technology in Malignant Skin Tumors. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	3

#	ARTICLE	IF	CITATIONS
785	Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes. <i>Genome Medicine</i> , 2022, 14, .	3.6	13
786	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. <i>Bladder Cancer</i> , 2022, 8, 291-301.	0.2	1
787	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Annals of Oncology</i> , 2022, 33, 968-980.	0.6	22
788	Heterogeneity in Melanoma. <i>Cancers</i> , 2022, 14, 3030.	1.7	10
789	The Role of Extracellular Vesicles in Melanoma Progression. <i>Cancers</i> , 2022, 14, 3086.	1.7	15
790	The pharmacotherapeutic management of nail unit and acral melanomas. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1273-1289.	0.9	2
791	cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach. <i>Cells</i> , 2022, 11, 2020.	1.8	34
792	Brain Somatic Variant in Ras-Like Small GTPase RALA Causes Focal Cortical Dysplasia Type II. <i>Frontiers in Behavioral Neuroscience</i> , 0, 16, .	1.0	0
795	Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies. <i>Nature Reviews Cancer</i> , 2022, 22, 515-532.	12.8	68
796	Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 859-867.	0.7	10
797	Two-Dimensional Borocarbonitride Nanosheet-Engineered Hydrogel as an All-In-One Platform for Melanoma Therapy and Skin Regeneration. <i>Chemistry of Materials</i> , 2022, 34, 6568-6581.	3.2	8
798	Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. <i>ESMO Open</i> , 2022, 7, 100540.	2.0	7
799	Dysplastic melanocytic nevus: Are molecular findings the key to the diagnosis?. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 152006.	0.6	3
800	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. , 2022, 10, e004879.		14
801	Type I collagen decorated nanoporous network on titanium implant surface promotes osseointegration through mediating immunomodulation, angiogenesis, and osteogenesis. <i>Biomaterials</i> , 2022, 288, 121684.	5.7	41
802	Identification of fusions with potential clinical significance in melanoma. <i>Modern Pathology</i> , 2022, 35, 1837-1847.	2.9	8
803	Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. , 2022, 10, e004668.		18
804	TERT Promoter Mutations and Telomerase in Melanoma. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	9

#	ARTICLE	IF	CITATIONS
805	Clinical and pathological characteristics of familial melanoma with germline <i>TERT</i> promoter variants. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 573-586.	1.5	2
806	Comparing the associations between host and tumor factors with survival outcomes with anti-PD-1 immunotherapy in metastatic melanoma. <i>Cancer Medicine</i> , 2023, 12, 2427-2439.	1.3	3
807	Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
808	Metabolic rewiring directs melanoma immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
809	Acral Melanocytic Neoplasms: A Comprehensive Review of Acral Nevus and Acral Melanoma in Asian Perspective. <i>Dermatopathology (Basel, Switzerland)</i> , 2022, 9, 292-303.	0.7	5
810	Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, 1-10.	0.7	1
811	Landscape of mutations in early stage primary cutaneous melanoma: An <i>InterMEL</i> study. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 605-612.	1.5	8
812	Cyclobutane Pyrimidine Dimer Hyperhotspots as Sensitive Indicators of Keratinocyte UV Exposure. <i>Photochemistry and Photobiology</i> , 2022, 98, 987-997.	1.3	4
813	Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature. <i>Modern Pathology</i> , 2022, 35, 1609-1617.	2.9	9
814	Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 1665-1676.	1.8	0
816	Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. <i>Journal of Medical Genetics</i> , 2022, 59, 1196-1205.	1.5	29
817	UVA Radiation, DNA Damage, and Melanoma. <i>ACS Omega</i> , 2022, 7, 32936-32948.	1.6	17
818	Advanced Acral Melanoma Therapies: Current Status and Future Directions. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1405-1427.	1.3	9
819	Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	3
820	Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. <i>Cancer Discovery</i> , 2022, 12, 2856-2879.	7.7	22
821	Comprehensive transcriptomic analysis of immune-related eRNAs associated with prognosis and immune microenvironment in melanoma. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
822	Two subtypes of cutaneous melanoma with distinct mutational signatures and clinico-genomic characteristics. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
823	Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma. <i>Journal of Investigative Dermatology</i> , 2023, 143, 18-25.e1.	0.3	6

#	ARTICLE	IF	CITATIONS
824	Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers—An Overview. <i>Gels</i> , 2022, 8, 560.	2.1	2
825	Adjuvant nivolumab therapy may not improve disease-free survival in resected acral lentiginous melanoma patients: A retrospective case series. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	2
826	Construction of five cuproptosis-related lncRNA signature for predicting prognosis and immune activity in skin cutaneous melanoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	11
827	Genomic profiling with whole-exome sequencing revealed distinct mutations and novel pathways in Asian melanoma. <i>Journal of Dermatology</i> , 2022, 49, 1299-1309.	0.6	3
828	Causes, consequences and clinical significance of aneuploidy across melanoma subtypes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
829	Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients. <i>European Journal of Cancer</i> , 2022, 176, 78-87.	1.3	13
830	Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. <i>Pathology</i> , 2022, , .	0.3	0
832	Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma. <i>Journal of Pathology</i> , 0, , .	2.1	1
833	Melanoma classification and management in the era of molecular medicine. <i>Dermatologic Clinics</i> , 2023, 41, 49-63.	1.0	15
835	Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma?. <i>Medicina (Lithuania)</i> , 2022, 58, 1398.	0.8	1
836	Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. <i>Gynecologic Oncology</i> , 2022, 167, 483-489.	0.6	4
838	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
839	Targeting the IL-2 pathway for the treatment of mucosal melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2022, 10, 34-47.	0.5	0
840	Expression profile and prognostic values of LSM family in skin cutaneous melanoma. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	3
841	Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	3
842	Solitary metastases presentation from uveal melanoma: report of three cases and a comprehensive review of the literature.. <i>Ocular Oncology and Pathology</i> , 0, , .	0.5	0
843	Expression and clinical significance of TYRP1, ABCB5, and MMP17 in sinonasal mucosal melanoma. <i>Cancer Biomarkers</i> , 2022, 35, 331-342.	0.8	2
844	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
845	YAP Activation in Promoting Negative Durotaxis and Acral Melanoma Progression. <i>Cells</i> , 2022, 11, 3543.	1.8	2
846	<scp>BRAF V600E</scp> immunohistochemistry as a useful tool in the diagnosis of melanomas with ambiguous morphologies and immunophenotypes. <i>Journal of Cutaneous Pathology</i> , 2023, 50, 223-229.	0.7	1
847	Genomic and proteomic findings in early melanoma and opportunities for early diagnosis. <i>Experimental Dermatology</i> , 2023, 32, 104-116.	1.4	1
848	TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma. <i>Science</i> , 2022, 378, 664-668.	6.0	8
849	Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 380-390.	1.8	2
850	In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis. <i>Biomedicines</i> , 2022, 10, 2961.	1.4	1
852	Oncogenic alterations reveal key strategies for precision oncology in melanoma treatment. <i>Annals of Translational Medicine</i> , 2022, 10, 1246-1246.	0.7	0
853	Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition. <i>Cancer Research</i> , 2023, 83, 316-331.	0.4	4
854	From Samples to Germline and Somatic Sequence Variation: A Focus on Next-Generation Sequencing in Melanoma Research. <i>Life</i> , 2022, 12, 1939.	1.1	1
855	Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15720.	1.8	13
856	Primary mucosal melanomas of the head and neck are characterised by overexpression of the <scp>DNA</scp> mutating enzyme <scp>APOBEC3B</scp>. <i>Histopathology</i> , 2023, 82, 608-621.	1.6	5
857	Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases. <i>Nature Communications</i> , 2022, 13, .	5.8	14
858	Immune checkpoint inhibitorâ€¢based therapy for advanced acral and mucosal melanoma. <i>Experimental Dermatology</i> , 2023, 32, 276-289.	1.4	6
859	Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5645-5653.	1.2	3
860	Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. <i>Clinical Cancer Research</i> , 2023, 29, 521-531.	3.2	5
861	Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma. <i>Genes and Diseases</i> , 2023, 10, 1755-1758.	1.5	1
862	Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
863	Resistance to immune checkpoint inhibitors and the tumor microenvironment. <i>Experimental Dermatology</i> , 2023, 32, 240-249.	1.4	5

#	ARTICLE	IF	CITATIONS
865	WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 391-407.	2.1	3
866	Melanogenesis and the Targeted Therapy of Melanoma. <i>Biomolecules</i> , 2022, 12, 1874.	1.8	9
867	Genomic comparison between an in vitro three-dimensional culture model of melanoma and the original primary tumor. <i>Archives of Dermatological Research</i> , 0, , .	1.1	0
868	Damage mapping techniques and the light they have shed on canonical and atypical UV photoproducts. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
869	Melanoma and Glioblastomaâ€”Not a Serendipitous Association. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	0
870	Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy. , 2023, 11, e005937.		0
871	Patient-specific identification of genome-wide DNA-methylation differences between intracranial and extracranial melanoma metastases. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
872	Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 317-332.	1.9	2
873	Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report. <i>BMC Medical Genomics</i> , 2023, 16, .	0.7	1
874	Characterisation and outcome of RAC1 mutated melanoma. <i>European Journal of Cancer</i> , 2023, 183, 1-10.	1.3	5
875	Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial. <i>European Journal of Cancer</i> , 2023, 182, 57-65.	1.3	7
876	Genomics and Epigenomics in the Molecular Biology of Melanomaâ€”A Prerequisite for Biomarkers Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 716.	1.8	3
877	Melanoma, molecular and genetic aspects of etiopathogenesis: classification, epidemiology, risk factors, braf and nras mutations. <i>Voprosy Onkologii</i> , 2022, 68, 725-732.	0.1	1
878	Deciphering gene contributions and etiologies of somatic mutational signatures of cancer. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	0
879	Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1963.	1.8	3
881	Cell Immortalization: In Vivo Molecular Bases and In Vitro Techniques for Obtention. <i>BioTech</i> , 2023, 12, 14.	1.3	2
882	Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma. <i>Computers in Biology and Medicine</i> , 2023, 154, 106602.	3.9	0
883	Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways. <i>Cancer Discovery</i> , 2023, 13, 1364-1385.	7.7	10

#	ARTICLE	IF	CITATIONS
884	eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma. <i>European Journal of Cancer</i> , 2023, 184, 120-123.	1.3	4
885	Localized immune surveillance of primary melanoma in the skin deciphered through executable modeling. <i>Science Advances</i> , 2023, 9, .	4.7	3
886	Pathologische Grundlagen und Anforderungen. , 2022, , 25-58.		0
887	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
888	Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. <i>IScience</i> , 2023, 26, 106096.	1.9	5
890	Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
891	Nanoemulsion and Nanogel Containing Cuminum cyminum L Essential Oil: Antioxidant, Anticancer, Antibacterial, and Antilarval Properties. <i>Journal of Tropical Medicine</i> , 2023, 2023, 1-11.	0.6	5
892	Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening. <i>Neuro-Oncology</i> , 2023, 25, 1507-1517.	0.6	8
893	Long Noncoding RNA SAMMSON Promotes Melanoma Progression by Inhibiting FOXA2 Expression. <i>Stem Cells International</i> , 2023, 2023, 1-22.	1.2	2
894	Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
896	Current Trends in Mucosal Melanomas: An Overview. <i>Cancers</i> , 2023, 15, 1356.	1.7	5
898	Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4430.	1.8	3
899	The effects of exposure to solar radiation on human health. <i>Photochemical and Photobiological Sciences</i> , 2023, 22, 1011-1047.	1.6	25
900	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4786.	1.8	0
901	Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene. <i>Melanoma Research</i> , 2023, 33, 247-251.	0.6	3
903	Molecular and genetic aspects of pathogenesis: somatic and germline mutations. <i>Voprosy Onkologii</i> , 2023, 69, 30-37.	0.1	0
904	Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5110.	1.8	1
905	Causes of Mutation Rate Variability in Plant Genomes. <i>Annual Review of Plant Biology</i> , 2023, 74, 751-775.	8.6	4

#	ARTICLE	IF	CITATIONS
906	The Network Zoo: a multilingual package for the inference and analysis of gene regulatory networks. <i>Genome Biology</i> , 2023, 24, .	3.8	4
907	UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. <i>Oncogene</i> , 2023, 42, 1360-1373.	2.6	2
908	Nail Apparatus Melanoma: Current Management and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2023, 12, 2203.	1.0	1
909	Update on nail unit histopathology. <i>Human Pathology</i> , 2023, 140, 214-232.	1.1	1
910	Age-related next-generation sequencing mutational analysis in 1196 melanomas. <i>Journal of Surgical Oncology</i> , 2023, 127, 1187-1195.	0.8	1
911	Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19.		0
912	ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma. <i>Cancer Research</i> , 2023, 83, 1128-1146.	0.4	5
913	Artificial intelligence reveals dysregulation of osteosarcoma and cuproptosis-related biomarkers, PDHA1, CDKN2A and neutrophils. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
914	Top 10 Basaloid Neoplasms of the Sinonasal Tract. <i>Head and Neck Pathology</i> , 2023, 17, 16-32.	1.3	0
915	Case Report: Identification of a rare nonsense mutation in the POC1A gene by NGS in a diabetes mellitus patient. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
916	Surgical resection margin for T3-T4 primary acral melanoma: a multicenter retrospective cohort study. <i>Archives of Dermatological Research</i> , 2023, 315, 2305-2312.	1.1	1
917	Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study. <i>Journal of Dermatological Science</i> , 2023, 110, 19-26.	1.0	4
918	Comparative oncology: overcoming human cancer through companion animal studies. <i>Experimental and Molecular Medicine</i> , 2023, 55, 725-734.	3.2	5
919	Comparative analysis of adjuvant therapy for stage <sc>III BRAF</sc> -mut melanoma: A real-world retrospective study from single center in China. <i>Cancer Medicine</i> , 0, , .	1.3	2
920	<i>streammd</i>: fast low-memory duplicate marking using a Bloom filter. <i>Bioinformatics</i> , 2023, 39, .	1.8	1
921	Research Progress of Single Cell Transcriptome Sequencing Technology in Cutaneous Malignant Melanoma. <i>Hans Journal of Biomedicine</i> , 2023, 13, 199-210.	0.0	0
922	Impact of risk factors on early cancer evolution. <i>Cell</i> , 2023, 186, 1541-1563.	13.5	12
923	Oncogenic <i>CDK13</i> mutations impede nuclear RNA surveillance. <i>Science</i> , 2023, 380, .	6.0	9

#	ARTICLE	IF	CITATIONS
924	Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
944	MÃ©lanomes cutanÃ©s malins. , 2023, , 229-230.		0
999	Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
1020	Experimental Models of Sinonasal Tumors for Preclinical Testing of Candidate Targeted Therapies. <i>Current Otorhinolaryngology Reports</i> , 2024, 12, 1-10.	0.2	1
1055	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	0
1058	è,çç«´é»è%²çççš,,è Šæ-â'Ææ²»ç—è;â±*. <i>Journal of Zhejiang University: Science B</i> , 2024, 25, 106-122.	1.3	0